A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex stock plummeted Thursday after the company's non-opioid pain drug proved it's no better than a placebo in patients ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

The scale lists the numbers one through ten with the number one representing the absence of pain and the number ten representing the worst pain imaginable. The nurse should explain the scale to ...

This 11-point scale ranges from 0 (no pain) to 10 (worst pain imaginable). The suzetrigine arm showed a statistically significant and clinically meaningful within-group reduction from baseline in pain ...